Today: 20 May 2026
Texas Instruments earnings shake up TXN stock as forecast tops estimates despite Q4 profit dip
27 January 2026
2 mins read

Texas Instruments earnings shake up TXN stock as forecast tops estimates despite Q4 profit dip

DALLAS, Texas, Jan 27, 2026, 15:27 (CST)

  • Texas Instruments’ revenue forecast for the March quarter topped Wall Street estimates, sending shares higher in after-hours trading
  • Q4 revenue climbed compared to last year, yet profit dipped slightly, weighed down by an unexpected per-share charge
  • Before the report, traders were largely betting on a beat, according to a prediction market

Texas Instruments projected first-quarter revenue between $4.32 billion and $4.68 billion on Tuesday, topping Wall Street’s average estimate of $4.42 billion and pushing TXN shares up almost 5% after hours. The analog-chip giant posted fourth-quarter revenue of $4.42 billion, just shy of forecasts. Its stock has gained over 13% this year, rebounding from a more than 7% drop in 2025 amid tariff-related concerns.

The outlook is crucial since Texas Instruments supplies the fundamental analog and embedded chips found in cars, factory machinery, and a wide range of consumer gadgets. Investors often view its guidance as a real-time indicator of everyday electronics demand, beyond just the components linked to data centers.

The analog market remains weighed down by an inventory hangover: buyers stocked up during the pandemic, then pulled back to clear their shelves. A forecast that beats estimates might suggest the cleanup is nearly finished, but it could also mislead if orders are just pushed into different quarters.

TI reported fourth-quarter revenue of $4.42 billion, up 10% from a year ago. Net income dipped to $1.16 billion, with earnings per share falling to $1.27, including a six-cent hit outside its original guidance. Analog sales jumped 14% to $3.62 billion, while embedded processing revenue climbed 8% to $662 million. For all of 2025, revenue hit $17.68 billion. CEO Haviv Ilan noted the company “returned $6.5 billion to owners” over the past year and added that “Revenue decreased 7% sequentially and increased 10% from the same quarter a year ago.” PR Newswire

After the regular session, TXN was trading near $207.48, according to Investors.com. The company’s guidance points to roughly $4.5 billion in sales for the March quarter and about $1.35 a share in earnings.

Expectations ran strong, even off the main track. On Polymarket, a site where users wager on real-world events, traders priced Texas Instruments at an 85% chance of topping the $1.31 per share estimate, according to TipRanks before the earnings drop.

The risk here is that the guidance signals timing quirks, not a solid rebound. Customers often “pull in” orders—buying earlier than expected—before tariff changes, which can inflate one quarter’s results and drain the next. KeyBanc analyst John Vinh noted, “China auto demand stays soft, and industrial weakness plus tariff-related pull-ins continue to cloud near-term visibility.” Barron’s

Texas Instruments goes head-to-head with rivals like Analog Devices and Microchip Technology in analog and embedded chips. In this space, extensive product ranges and longevity often outweigh cutting-edge speed. Demand here tracks factory production and vehicle assembly more closely than the AI spending boom.

Ilan has ramped up spending on manufacturing, focusing on bigger 300-millimeter wafers — larger silicon slices that can cut per-chip costs when plants operate at full tilt. While this investment boosts capacity, it also puts cash flow under close watch from investors holding TXN for dividends.

At this stage, the results are mixed: Q4 profits took a hit, yet the outlook came in stronger than expected. Tariffs continue to cloud the demand picture. The real challenge will be if orders hold up once easy comparisons disappear and customers quit “buying ahead.”

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Micron stock jumps after $24 billion Singapore fab plan; MU investors turn to pricing and capex
Previous Story

Micron stock jumps after $24 billion Singapore fab plan; MU investors turn to pricing and capex

Oracle stock slides 4% as AI spending scrutiny builds ahead of Fed decision
Next Story

Oracle stock slides 4% as AI spending scrutiny builds ahead of Fed decision

Go toTop